Monkeypox Vaccine Priority Recipient

Until now, the monkeypox vaccine has been the best alternative for patients. This viral disease can go away in a few days, but the symptoms that appear cause discomfort and must be treated immediately.

The disease has sparked global concern in recent times following the outbreak of the COVID-19 virus. Until now, there has been no specific treatment for monkeypox symptoms. However, the vaccine is claimed to be able to prevent transmission.

Also Read: Robotic Surgery Development Challenges in Indonesia

Although vaccines can prevent the risk of transmission, especially in healthy people, their administration must be based on effectiveness. The virus that causes monkeypox is not easily transmitted. So it is only given to some, like the covid-19 vaccine.

2 groups that are vulnerable to infection

There are 2 groups of people who are very susceptible to infection. This group is a priority for giving monkeypox vaccines to minimize contracting the disease. The target of giving is people exposed and groups with high risk.

People affected are seen by symptoms such as rash, fever, and so on. While people fall into high-risk groups as follows:

People who have close contact with someone who is infected with monkeypox. This group is very likely to be contaminated due to accidental touch.

• Have had sex with someone who tested positive for monkeypox. This group also has a high potential for infection, especially when the immune condition is not prime.
• Work in laboratories and handle orthopoxvirus samples or animals. This group is tantamount to direct contact with the cause of the monkeypox disease itself.
• Health workers. Same as for groups 1 and 3, the risk of coming into contact with the suspect is very high.
• Children under the age of 8 years. Children at this age are still susceptible to illness because their immune system is not optimal.

Outside this group, getting the monkeypox vaccine is not recommended because the administration is not only practical but also causes side effects, such as pain, redness, swelling at the injection site, itching, headache, nausea, chills, and fatigue.

Distribution of Monkeypox Vaccine

The United States Food and Drug Administration (FDA) approved 2 types of vaccines that can provide protection. It can be given to patients who have shown symptoms or vulnerable groups.

Also Read: BMHS Scholarship Program

JYNNEOS

The monkeypox vaccine is also called immune or imvanex. It contains live vaccinia virus, designed to prevent infection in people at high risk of monkeypox.

It is given in two doses. The second injection is given one month after the first dose. It takes 14 days after the double dose for the body to build a robust immune response to the virus.

The FDA has approved 2 doses for ages 18 and older. As for those who have received the chickenpox vaccine as a baby, it only takes 1 quantity.

The JYNNE monkeypox vaccine is safe for people with immune diseases such as HIV, and it can also be given to people with eczema or other skin conditions.

ACAM2000

ACAM2000 is used against smallpox, and it contains live viruses that are capable of reproducing. The reaction to administration is in the form of small lesions or red and itchy bumps that form 3-4 days after the injection, which heals in 6 weeks.

After the second dose, it takes the body approximately four weeks to build an immune response to the virus. After that, the symptoms and all complaints as side effects of vaccination will disappear.

In addition to relying on treatment, people susceptible to exposure must adopt a healthy lifestyle. Meet all the needs of balanced nutritional food and implement clean living. This habit also increases the effectiveness of the monkeypox vaccine.

Also Read: BKOW Collaborates with RSU Bunda Padang to Fight Stunting Indonesia

Find out more about Indonesia's health news here. You can also find information on BMHS's CSR activities here, and their assets here.

Reviewed by:

dr. Harmeni Wijaya, MD
Corporate Communications
PT Bundamedik Tbk